Kexing Biopharm Co., Ltd. (SHA:688136)

Market Cap	4.11B -52.7%
Revenue (ttm)	1.46B +4.4%
Net Income	112.05M +150.9%
EPS	0.57 +149.3%
Shares Out	197.86M
PE Ratio	36.65
Forward PE	33.53
Dividend	0.25 (1.20%)
Ex-Dividend Date	Jun 15, 2026

Volume	8,805,484
Open	20.96
Previous Close	20.79
Day's Range	20.68 - 22.22
52-Week Range	17.18 - 58.00
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 22, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05, a human interferon a1b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,048
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688136

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.53 billion, an increase of 9.03% compared to the previous year's 1.41 billion. Earnings were 155.57 million, an increase of 394.17%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 15, 2026

Data Sources Report a data error